<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03127319</url>
  </required_header>
  <id_info>
    <org_study_id>AHHU-2017AMZ01</org_study_id>
    <nct_id>NCT03127319</nct_id>
  </id_info>
  <brief_title>A Study of Apatinib Plus Docetaxel for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With Bone Metastases</brief_title>
  <official_title>A Study of Apatinib Plus Docetaxel for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With Bone Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affiliated Hospital of Hebei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Affiliated Hospital of Hebei University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of patients who receive&#xD;
      apatinib plus docetaxel and zoledronic versus docetaxel and zoledronic alone as second line&#xD;
      treatment for advanced non-squamous non-small cell lung cancer with bone metastases.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 3, 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>evaluation per 2 cycles (6 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>evaluation per 2 cycles (6 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR (Disease control rate)</measure>
    <time_frame>evaluation per 2 cycles (6 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR (Objective response rate)</measure>
    <time_frame>evaluation per 2 cycles (6 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SREs（Skeletal-related events）</measure>
    <time_frame>evaluation per 2 cycles (6 weeks)</time_frame>
    <description>measured pain, a fracture, the need for bone radiation or surgical therapy, spinal cord compression, or hypercalcemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0</measure>
    <time_frame>evaluation per 2 cycles (6 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Non-squamous Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>apatinib and docetaxel zoledronic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>apatinib 500mg qd po; docetaxel 60mg/m² iv q3w; zoledronic 4mg iv&gt;15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>docetaxel zoledronic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>docetaxel 60mg/m² iv q3w;zoledronic 4mg iv&gt;15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>apatinib docetaxel zoledronic</intervention_name>
    <description>apatinib 500 mg qd p.o.docetaxel 60mg/m² iv q3w;zoledronic 4mg iv&gt;15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent</description>
    <arm_group_label>apatinib and docetaxel zoledronic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel zoledronic</intervention_name>
    <description>docetaxel 60mg/m² iv q3w;zoledronic 4mg iv&gt;15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent</description>
    <arm_group_label>docetaxel zoledronic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age:18 to 75 years old (man or female)&#xD;
&#xD;
          2. Pathologically diagnosed with metastatic or recurrent non-squamous non-small cell lung&#xD;
             cancer&#xD;
&#xD;
          3. Patients with at least one evaluate lesions of the lung and bone&#xD;
             metastases.(measuring≥10mm on spiral CT scan, satisfying the criteria in RECIST1.1 and&#xD;
             WHO)&#xD;
&#xD;
          4. Refractory or failure of prior therapy&#xD;
&#xD;
          5. Life expectancy greater than or equal to 3 months&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2&#xD;
&#xD;
          7. Major organ function has to meet the following criteria:&#xD;
&#xD;
               -  For results of blood routine test (without blood transfusion within 14 days)&#xD;
&#xD;
                    1. HB≥90g/L&#xD;
&#xD;
                    2. ANC≥1.5×109/L&#xD;
&#xD;
                    3. PLT≥180×109/L&#xD;
&#xD;
               -  For results of blood biochemical test：&#xD;
&#xD;
                    1. TBIL&lt;1.5×ULN；&#xD;
&#xD;
                    2. ALT and AST&lt;2.5×ULN, but&lt; 5×ULN if the transferase elevation is due to liver&#xD;
                       metastases；&#xD;
&#xD;
                    3. Serum creatinine ≤1.25×ULN , or calculated creatinine clearance&gt;45&#xD;
                       ml/min(per the Cockcroft-Gault formula);&#xD;
&#xD;
          8. Women of childbearing age must have contraceptive measures or have test pregnancy&#xD;
             (serum or urine) enroll the study before 7 days, and the results must be negative, and&#xD;
             take the methods of contraception during the test and the last to have drugs after 8&#xD;
             weeks. Men must be contraception or has sterilization surgery during the test and the&#xD;
             last to have drugs after 8 weeks;&#xD;
&#xD;
          9. Participants were willing to join in this study, and written informed consent, good&#xD;
             adherence, cooperate with the follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergic to apatinib and docetaxel;&#xD;
&#xD;
          2. Have high blood pressure and antihypertensive drug treatment can not control (systolic&#xD;
             blood pressure &gt; 140 mmHg, diastolic blood pressure &gt; 90 mmHg), with class Ⅱ and above&#xD;
             coronary heart disease, arrhythmia (including QTc lengthened men &gt; 450 ms, women &gt; 470&#xD;
             ms) and class Ⅲ-Ⅳ cardiac insufficiency;&#xD;
&#xD;
          3. A variety of factors influencing oral drugs (such as unable to swallow, nausea,&#xD;
             vomiting, chronic diarrhea and intestinal obstruction, etc.).&#xD;
&#xD;
          4. Patients with tendency of gastrointestinal bleeding, including the following: a local&#xD;
             active ulcerative lesions, and defecate occult blood (+ +); Has melena and hematemesis&#xD;
             in two months; For defecate occult blood (+) and primary lesions without surgical&#xD;
             removal of the stomach tumor, requirement of gastroscopy, such as ulcer type of&#xD;
             gastric cancer, and researchers think that may be gastrointestinal hemorrhage;&#xD;
&#xD;
          5. Coagulant function abnormality (INR &gt; 1.5 ULN, APTT &gt; 1.5 ULN), with bleeding&#xD;
             tendency.&#xD;
&#xD;
          6. Patients with symptoms of central nervous system metastasis.&#xD;
&#xD;
          7. Pregnant or lactating women.&#xD;
&#xD;
          8. history of psychiatric drugs abuse and can't quit or patients with mental disorders.&#xD;
&#xD;
          9. Less than 4 weeks from the last clinical trial.&#xD;
&#xD;
         10. The researchers think inappropriate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aimin Zang</last_name>
    <phone>13930881628</phone>
    <email>15175292891@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Affiliated Hospital of Hebei university</name>
      <address>
        <city>BaoDing</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aimin Zang</last_name>
      <phone>13930881628</phone>
      <email>15175292891@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>December 30, 2016</study_first_submitted>
  <study_first_submitted_qc>April 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2017</study_first_posted>
  <last_update_submitted>January 14, 2018</last_update_submitted>
  <last_update_submitted_qc>January 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Affiliated Hospital of Hebei University</investigator_affiliation>
    <investigator_full_name>Aimin Zang</investigator_full_name>
    <investigator_title>Director of oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

